



## **Antivirals – HIV Combinations**

Please fax this completed form to (866) 399-0929 OR mail to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720.

Date of request:	Reference #:		MAS:			
Patient	Date of birth		ProviderOne ID or Coordinated Care ID			
Pharmacy name	Pharmacy NPI	Telephone number		Fax number		
Prescriber	Prescriber NPI	Telepho	Telephone number Fax		ax number	
Medication and strength		Dire	Directions for use		Qty/Days supply	
Is this request for a continuation of existing therapy?    Yes    No     If yes, has patient shown continued medication adherence with no breaks in therapy?    Yes    No						
2. What is patient's diagnosis?  HIV-1  Other. Specify:						
3. Is patient treatment naïve?  Yes  No						
<ul> <li>4. Does patient have Hepatitis B virus (HBV)? Yes No If yes: Is hepatic function being closely monitored? Yes No Has patient initiated an anti-HBV treatment? Yes No </li> </ul>						
5. What is the patient's current weight? kg Date taken:						
6. Does patient have hepatic impairment? Yes No  If yes: Moderate (Child-Pugh Class B) Severe (Child-Pugh Class C)  Other. Specify:						
7. What is the patient's creatinine clearance? mL/min Date taken:						
8. Will patient be using any of the following medications? (check all that apply)						
Alfusozin  Dexamethaso  Elbasvir  Ivabradine  Mitotane  Phenytoin  Rifampin  St John's Wor	Enzalutamide Lurasidone Naloxegol Pimozide Rifapentine	ĺ	Colchicine Dronedar Ergot Der Lomitapid Oxcarbaze PPIs Sildenafil	one ivatives de	Cisapride Elbasivir/Grazoprevir Grazoprevir Midazolam Phenobarbital Ranolazine Statins	
9. If patient is of childbearing potential, does patient have a confirmed negative pregnancy test?   Yes No						
10. Does patient have an inability to maintain an undetectable viral load on preferred separate agents due to non-adherence? Yes No						

11. Is this prescribed by or in consultation with a specialist in infectious disease or HIV? Yes No						
Complete only for:						
Lamivudine/tenofovir disoproxil (Temixys):						
12. Does patient have a documented allergy to inactive ingredients contained in commercially separate agents <b>AND</b> Cimduo? Yes No						
Complete only for:						
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza):						
13. Has patient been stable on an ART regimen for at least the past 6 months with no history of treatment of treatment failure on current regimen?						
Complete only for: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)						
High risk for bon Arm or h Vertebra Chronic I T-score	emodialysis  n with family history of kidney disease e complications as determined by a hist ip fracture with minimal trauma il compression factor kidney with proteinuria, low phosphate s -2.0 (DXA) at the femoral neck or spine	or is grade 3 or worse				
Chronic, high-dose glucocorticoid-therapy (5 mg/day of prednisone or equivalent for at more						
than two (2) months						
<ul> <li>What is the diagnosis requiring glucocorticoid regimen?</li> <li>What is patient's current glucocorticoid regimen?</li> </ul>						
<ul> <li>What is patient's current glucocorticold regimen?</li> <li>What is the expected duration of therapy of glucocorticold regimen?</li> </ul>						
- What is the expected duration of therapy of glacocorticola regimen;						
C	HART NOTES ARE REQUIRED WITH THI	S REQUEST				
Prescriber signature	Prescriber specialty	Date				

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)